help button home button Am J Pathol R & D Systems
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Originally published online as doi:10.2353/ajpath.2008.070724 on March 5, 2008

Published online before print March 5, 2008
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
ajpath.2008.070724v1
172/4/1062    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hornsby, C.
Right arrow Articles by Tomlinson, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hornsby, C.
Right arrow Articles by Tomlinson, I.
(American Journal of Pathology. 2008;172:1062-1068.)
© 2008 American Society for Investigative Pathology
DOI: 10.2353/ajpath.2008.070724

The in Vivo Rate of Somatic Adenomatous Polyposis Coli Mutation

Chris Hornsby*, Karen M. Page{dagger} and Ian Tomlinson{ddagger}

From the Departments of Computer Science,* and Mathematics,{dagger} University College; and the Molecular and Population Genetics Laboratory,{ddagger} London Research Institute, Cancer Research UK, London, United Kingdom

Cancer arises through successive somatic mutations/epimutations of oncogenes and tumor-suppressor genes. Accurate estimates of the rates at which these (epi)mutations occur are a vital but missing link in our emerging quantitative understanding of tumorigenesis. Their absence has hindered arguments concerning the importance of genetic instability in tumorigenesis and the number of mutations that precede malignant conversion of healthy cell lineages. Herein, a novel method for calculating the in vivo mutation rate of the adenomatous polyposis coli (APC) tumor-suppressor gene is presented. The large majority of bowel cancers are thought to be initiated by a partial loss of APC function, with the age-onset pattern dramatically altered for the worse in familial adenomatous polyposis (FAP) because these patients harbor selected germline APC mutations. Colon cancer in the context of FAP can be thought of as occurring "one hit quicker" than in the sporadic setting. We were able to isolate and estimate the rate of the initiating APC mutation in sporadic cases using the age incidence of FAP to approximate the time taken for a cell lineage in a sporadic patient with one APC mutation to present clinically as a cancer. Our result of approximately 10–5 mutations per allele per year, although higher than previous estimates, appears to be consistent with the mutational spectrum of APC. The quality of fit provided by this method supports the theory that FAP and sporadic bowel cancer follow the same genetic pathway and are separated by only one mutation.




This article has been cited by other articles:


Home page
 Hum Mol GenetHome page
E. M. Kohler, S. H. V. Chandra, J. Behrens, and J. Schneikert
{beta}-Catenin degradation mediated by the CID domain of APC provides a model for the selection of APC mutations in colorectal, desmoid and duodenal tumours
Hum. Mol. Genet., January 15, 2009; 18(2): 213 - 226.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American Society for Investigative Pathology.